Hye Jin Im

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Combination therapy of intravenous immunoglobulin (IVIG) and rituximab showed a good transplant rate in highly sensitized wait-listed patients for deceased donor kidney transplantation (DDKT), but carried the risk of antibody-mediated rejection. The authors investigated the impact of a new combination therapy of bortezomib, IVIG, and rituximab on(More)
  • 1